Our Take
A replicable animal model that mirrors human genetic diversity is valuable, but a liver enzyme target in rats does not yet predict a human drug; the translational gap remains wide.
Why it matters
Cocaine use disorder has ~70% heritability (per twin studies cited in the paper), yet human genetic links remain sparse. A validated rat model that reproduces known human loci (Trak2) creates a testable framework for identifying therapies—but only if the liver-enzyme pathway holds in humans.
Do this week
Drug discovery teams: flag Ces1-targeted small molecules for preclinical validation in the UC San Diego Preclinical Addiction Biobanks before committing to IND-enabling studies, so you can de-risk the human translation.
Nearly 900 rats reveal liver enzyme tied to cocaine compulsion
Researchers at UC San Diego conducted a genome-wide association study (GWAS) in Heterogeneous Stock rats—a genetically diverse outbred model—to identify genetic drivers of cocaine self-administration. The study, published in Nature Communications and led by Olivier George and Abraham Palmer, analyzed millions of genetic markers per animal and uncovered six major genetic regions linked to escalating drug intake and compulsive use patterns despite negative consequences.
The team identified carboxylesterase genes (Ces1 in rats, orthologous to human CES1) responsible for metabolizing cocaine. Variations in these genes correlated strongly with how frequently and compulsively rats self-administered the drug. The study also replicated Trak2, a genetic link already identified in human GWAS of cocaine use disorder, providing a bridge between animal findings and human biology.
The shift in focus is notable: instead of targeting brain mechanisms alone, the researchers propose that how the body metabolizes cocaine—via liver enzymes—may be equally critical in determining addiction vulnerability. The team plans to investigate exactly how Ces1 mutations alter enzyme function and to leverage the study's Preclinical Addiction Biobanks (collections of blood, urine, brain, and tissue samples) to identify biological markers for predicting individual addiction risk.
The translational reality: a validated pathway does not yet mean a drug
Cocaine use disorder has strong heritable components (70% heritability per twin studies, 27–30% per SNP-based heritability estimates, per the paper). However, human GWAS efforts have produced few replicated gene associations, limiting the ability to identify novel drug targets. The UC San Diego study addresses this by using a rat model that captures the genetic diversity present in human populations—a methodological strength.
The replication of Trak2 strengthens confidence in the rat model's relevance. But replicating one human locus in an animal system is not the same as proving that a rat Ces1 inhibitor will reduce addiction in humans. The liver enzyme finding is intriguing because it suggests a metabolic angle not yet heavily pursued, but the claim that targeting Ces1 could "alter how the drug affects the body" and "blunt the drive toward compulsive use" rests entirely on rodent data. Human validation—whether through genetic association, population studies, or eventually clinical trials—remains years away.
Practitioners should note: this is a discovery-stage finding with legitimate potential, not a target ready for rapid translation.
Next steps for addiction research and pharma teams
For researchers working on substance use disorder genetics, the UC San Diego dataset and methodology offer a replicable template. The Heterogeneous Stock rat model can be applied to other addiction phenotypes and validated against human GWAS cohorts as larger human datasets emerge.
For drug discovery teams evaluating Ces1 as a target, the immediate action is comparative validation: test whether Ces1 inhibition in rodent models replicates the team's genetic associations before advancing to lead optimization. The liver-enzyme pathway is underexplored relative to brain-centric approaches, but that alone does not guarantee clinical utility. Use the biobanks and the team's extended behavioral phenotyping as a resource to de-risk early-stage programs.
For funding bodies and institutional leadership, the study underscores the value of long-term, multi-cohort collaborations—a decade of coordinated effort across federal partners was required. Budget accordingly.